Home › Compare › WALRF vs ABBV
WALRF yields 2436.05% · ABBV yields 3.06%● Live data
📍 WALRF pulled ahead of the other in Year 1
Combined, WALRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of WALRF + ABBV for your $10,000?
MegaWatt Lithium and Battery Metals Corp. engages in the acquisition, exploration, and development of mineral properties in Canada and Australia. It holds a 100% interest in the Route 381 Lithium property that consists of 40 mineral claims covering an area of approximately 2,126 hectares located in James Bay Territory in the Province of Quebec. The company also holds interest in the Tyr silver project and Century South silver-zinc project located in Australia. In addition, it holds an option to acquire a 100% interest in the Cobalt Hill property that consists of eight mineral claims covering an area of approximately 1,727.43 hectares located in the Trail Creek Mining division in British Columbia. The company was formerly known as Walcott Resources Ltd. and changed its name to MegaWatt Lithium and Battery Metals Corp. in February 2021. MegaWatt Lithium and Battery Metals Corp. was incorporated in 2017 and is based in Vancouver, Canada.
Full WALRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.